|
|
|
|
Programme Coordinator:
CO BIK - Centre of Excellence for Biosensors,
Instrumentation and Process Control
Partners:
National Institute of
Chemistry, Lek d.d., Metronik d.o.o., National Institute of Biology, BIA
d.o.o., UL Faculty of Electrical Engineering, UL Faculty of Computer and
Information Science, Faculty of Chemistry and Chemical Technology,
Instrumentation Technologies d.d.
Project value: 8.810.160,00 EUR
Amount of co-financing: 5.972.371,63 EUR
Priority area: Health - Medicine
Period of the programme: 14.07.2016 - 30.06.2020
Description of the programme:
The main goal of
BioPharm.Si programme, involving high tech and biotech Slovenian companies and
excellent research institutions, is development of continuous manufacturing
processes and innovative devices and services that will facilitate transition from batch to fully
continuous manufacturing of biologics.
Manufacturing of biologics
and vaccines in the form of proteins, DNA, and viruses is operationally and
technologically challenging. Producing large molecules reproducibly on an
industrial scale requires manufacturing capabilities with a previously unknown
sophistication. Conventionally, the biologics manufacturing process is done in
batch mode, where each production step starts and ends independently from the
previous and following step. Therefore,
the goal of biopharmaceutical industry is in the transition from batch
processing to fully continuous processing, mainly to increase productivity,
maximize flexibility, simplify scale-up and process transfers, increase
robustness, and minimize cost of goods while still maintaining operational
excellence.
The programme focus is on
seven key areas: http://www.biopharm.si. LMSE staff are involved in RDP2
– Monitoring Quality of Biologics.
The expected results of the programme:
-
25 innovations and 6 patents,
-
10 % increase of private investments in R&D,
-
4 prototypes, 5 new methods, and 4 services for the
global market,
-
Developing technologies, services and products for
the global market,
-
At least one newly established company is foreseen
that will pick up some of these technologies, develop hi-tech products and
enter the global market,
-
An 8% increase in the added value of companies per
employee by 2020 and an additional 5% by 2023,
-
Employment of at least 26 new researchers and
engineers,
-
At least 9 collaboration projects between industry
and academia.